One of the greatest challenges in biomedicine is the Translational Dilemma: the inability to effectively and efficiently translate the ever-increasing basic knowledge about the pathophysiology of diseases into effective clinical therapeutics. Translational Systems Biology and In Silico Trials section should address the challenge of bridging these gaps.Read More
One of the greatest challenges in biomedicine is the Translational Dilemma: the inability to effectively and efficiently translate the ever-increasing basic knowledge about the pathophysiology of diseases into effective clinical therapeutics. There are multiple reasons for the “Valley of Death” of drug development, including the gap between the representational fidelity of pre-clinical experimental models and clinical disease and an inability to account for the true heterogeneity of clinical populations. We posit that the use of Translational Systems Biology within the drug development pipeline will increase the efficiency of crossing the “Valley of Death” and aim to promote this goal within this section. Thus, manuscripts published within the Translational Systems Biology and In Silico Trials section should address the challenge of bridging these gaps through the use of dynamic mathematical and computational models to:
Abstract disease processes
Represent the pharmacologic impact of drugs on diseases mechanistically and quantitatively
Simulate individual human responses (“digital twins”)
The following types of submissions are not appropriate for this section: work that focuses solely on pre-clinical models; descriptive network models without some dynamic representation of biological mechanisms; machine learning/artificial intelligence or other statistical models that focus only on diagnosis and prognosis without some representation of potential interventions.
Indexed in: CLOCKSS, CrossRef, Google Scholar, OpenAIRE
Translational Systems Biology and In Silico Trials welcomes submissions of the following article types: Brief Research Report, Case Report, Clinical Trial, Community Case Study, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Policy Brief, Protocols, Review, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Translational Systems Biology and In Silico Trials, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org